CO5580744A2 - Forma de dosificacion oral de un profarmaco de sulfonamida - Google Patents
Forma de dosificacion oral de un profarmaco de sulfonamidaInfo
- Publication number
- CO5580744A2 CO5580744A2 CO04042439A CO04042439A CO5580744A2 CO 5580744 A2 CO5580744 A2 CO 5580744A2 CO 04042439 A CO04042439 A CO 04042439A CO 04042439 A CO04042439 A CO 04042439A CO 5580744 A2 CO5580744 A2 CO 5580744A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- drug
- compound
- nhr1
- parecoxib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una composición farmacéutica sustancialmente anhidra y que comprende al menos una unidad de dosificación que comprende una cantidad terapéuticamente efectiva de un compuesto X-SO2-NHR1, o una sal farmacéuticamente aceptable de éste, en el que X es un resto seleccionado de manera que el compuesto X-SO2-NH2 es un fármaco conocido, siendo el compuesto X-SO2-NHR1 o una sal de éste fácilmente degradables ex vivo al fármaco X-SO2-NH2; y en el que R1 es un grupo, que no tiene más de 8 átomos de carbono, seleccionado de entre los grupos alquilo, hidroxialquilo, alcoxialquilo, carboxialquilo, acilo, alquilcarbonilo, alcoxicarbonilo, hidroxialquilcarbonilo, alcoxialquilcarbonilo, carboxialquilcarbonilo, aminoalquilcarbonilo, fenilcarbonilo, bencilcarbonilo, fenil(hidroxi)metilcarbonilo, alcoxicarbonilcarbonilo, alcoxicarbonilalquilcarbonilo, alcoxicarbonilalquilcarbonilo, alquilcarbonilaminoalquilcarbonilo, alcoxicarbonilaminoalquilcarbonilo, alcoxicarbonilcarbonilo, resto de aminoácido y grupos heteroarilcarbonilo; siendo dicha composición administrable por vía oral y con medios para inhibir la degradación del compuesto X-SO2-NHR1 o una sal de éste al fármaco X-SO2-NH2 previa a la administración oral.2.- La composición de la reivindicación 1 en la que el fármaco X-SO2-NH2 es un fármaco inhibidor selectivo de la COX-2.3.- La composición de la reivindicación 1 en la que el fármaco X-SO2-NH2 se selecciona de entre el grupo que comprende valdecoxib, celecoxib y deracoxib.4.- La composición de la reivindicación 1 en la que el compuesto X-SO2- NHR1 es parecoxib y se presenta en forma del ácido libre de parecoxib o como una sal farmacéuticamente aceptable de éste soluble en agua.5.- La composición de la reivindicación 4 en la que la cantidad de parecoxib o de una sal soluble en agua de éste en cada unidad de dosificación es de aproximadamente 1 mg a aproximadamente 200 mg.6.- La composición de la reivindicación 4 en la que la cantidad de parecoxib o de una sal soluble en agua de éste en cada unidad de dosificación es de aproximadamente 5 mg a aproximadamente 120 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35059601P | 2001-11-13 | 2001-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580744A2 true CO5580744A2 (es) | 2005-11-30 |
Family
ID=23377399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04042439A CO5580744A2 (es) | 2001-11-13 | 2004-05-07 | Forma de dosificacion oral de un profarmaco de sulfonamida |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030100595A1 (es) |
| EP (1) | EP1446118B1 (es) |
| JP (1) | JP2005509002A (es) |
| KR (1) | KR20050044459A (es) |
| CN (1) | CN1615135A (es) |
| AR (1) | AR037356A1 (es) |
| AT (1) | ATE383156T1 (es) |
| BR (1) | BR0214081A (es) |
| CA (1) | CA2466504A1 (es) |
| CO (1) | CO5580744A2 (es) |
| DE (1) | DE60224558T2 (es) |
| ES (1) | ES2297032T3 (es) |
| IL (1) | IL161991A0 (es) |
| MX (1) | MXPA04004476A (es) |
| NO (1) | NO20042440L (es) |
| PL (1) | PL369962A1 (es) |
| RU (1) | RU2004114552A (es) |
| TW (1) | TW200300680A (es) |
| WO (1) | WO2003041705A1 (es) |
| ZA (1) | ZA200403328B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785640B2 (en) * | 2004-01-16 | 2010-08-31 | Amerilab Technologies, Inc. | Effervescent composition including cranberry extract |
| PT2801355E (pt) | 2004-10-08 | 2015-09-18 | Forward Pharma As | Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico |
| WO2007038421A2 (en) * | 2005-09-27 | 2007-04-05 | University Of Kentucky Research Foundation | Berry preparations and extracts |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| CA2661274A1 (en) * | 2006-08-29 | 2008-03-06 | University Of Kentucky Research Foundation | Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
| EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| TW200924768A (en) * | 2007-10-12 | 2009-06-16 | Astrazeneca Ab | Composition |
| EP2564839B1 (en) | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| JP6102120B2 (ja) * | 2012-08-16 | 2017-03-29 | ニプロ株式会社 | 医薬製剤およびその製造方法 |
| CN104771370B (zh) * | 2014-01-14 | 2020-07-24 | 南京圣和药业股份有限公司 | 帕瑞昔布钠冻干粉针剂及其制备方法 |
| CN104965041B (zh) * | 2015-06-11 | 2016-06-29 | 成都克莱蒙医药科技有限公司 | 一种帕瑞昔布钠异构体的高效液相色谱检测方法 |
| CN106074399B (zh) * | 2016-06-21 | 2018-11-02 | 马鞍山丰原制药有限公司 | 一种帕瑞昔布钠冻干制剂及其制备方法 |
| CN112409283A (zh) * | 2020-11-24 | 2021-02-26 | 苏州璞正医药有限公司 | 一种帕瑞昔布衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0729748B1 (en) * | 1993-11-18 | 2003-02-26 | Nippon Shinyaku Company, Limited | Process for producing stable medicinal composition |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| RO121338B1 (ro) * | 1996-04-12 | 2007-03-30 | G.D. Searle & Co. | Derivaţi de benzensulfonamidă, procedeu de preparare a acestora, compoziţie farmaceutică şi utilizarea ca inhibitori de cox-2 |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
| CA2362816C (en) * | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Valdecoxib compositions |
| CZ300745B6 (cs) * | 1999-12-22 | 2009-07-29 | Pharmacia Corporation | Kompozice inhibitoru cyklooxygenázy-2 s dvojím uvolnováním |
| JP4216502B2 (ja) * | 2000-03-24 | 2009-01-28 | ファルマシア コーポレーション | 酸化窒素シンターゼ阻害剤として有用なアミジノ化合物 |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
| AU2001282886A1 (en) * | 2000-07-13 | 2002-01-30 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| PE20021017A1 (es) * | 2001-04-03 | 2002-11-24 | Pharmacia Corp | Composicion parenteral reconstituible |
-
2002
- 2002-11-12 AR ARP020104341A patent/AR037356A1/es unknown
- 2002-11-12 RU RU2004114552/14A patent/RU2004114552A/ru not_active Application Discontinuation
- 2002-11-12 JP JP2003543592A patent/JP2005509002A/ja active Pending
- 2002-11-12 BR BR0214081-0A patent/BR0214081A/pt not_active IP Right Cessation
- 2002-11-12 US US10/292,682 patent/US20030100595A1/en not_active Abandoned
- 2002-11-12 EP EP02789593A patent/EP1446118B1/en not_active Expired - Lifetime
- 2002-11-12 MX MXPA04004476A patent/MXPA04004476A/es active IP Right Grant
- 2002-11-12 CA CA002466504A patent/CA2466504A1/en not_active Abandoned
- 2002-11-12 KR KR1020047007335A patent/KR20050044459A/ko not_active Application Discontinuation
- 2002-11-12 IL IL16199102A patent/IL161991A0/xx unknown
- 2002-11-12 CN CNA028270843A patent/CN1615135A/zh active Pending
- 2002-11-12 PL PL02369962A patent/PL369962A1/xx not_active Application Discontinuation
- 2002-11-12 AT AT02789593T patent/ATE383156T1/de not_active IP Right Cessation
- 2002-11-12 DE DE60224558T patent/DE60224558T2/de not_active Expired - Fee Related
- 2002-11-12 WO PCT/US2002/036253 patent/WO2003041705A1/en active IP Right Grant
- 2002-11-12 ES ES02789593T patent/ES2297032T3/es not_active Expired - Lifetime
- 2002-11-12 TW TW091133146A patent/TW200300680A/zh unknown
-
2004
- 2004-05-03 ZA ZA200403328A patent/ZA200403328B/en unknown
- 2004-05-07 CO CO04042439A patent/CO5580744A2/es not_active Application Discontinuation
- 2004-06-11 NO NO20042440A patent/NO20042440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1446118A1 (en) | 2004-08-18 |
| US20030100595A1 (en) | 2003-05-29 |
| EP1446118B1 (en) | 2008-01-09 |
| IL161991A0 (en) | 2005-11-20 |
| BR0214081A (pt) | 2004-09-28 |
| DE60224558D1 (de) | 2008-02-21 |
| ATE383156T1 (de) | 2008-01-15 |
| TW200300680A (en) | 2003-06-16 |
| RU2004114552A (ru) | 2005-02-20 |
| ES2297032T3 (es) | 2008-05-01 |
| KR20050044459A (ko) | 2005-05-12 |
| WO2003041705A1 (en) | 2003-05-22 |
| PL369962A1 (en) | 2005-05-02 |
| AR037356A1 (es) | 2004-11-03 |
| CN1615135A (zh) | 2005-05-11 |
| CA2466504A1 (en) | 2003-05-22 |
| DE60224558T2 (de) | 2009-01-22 |
| MXPA04004476A (es) | 2004-08-11 |
| ZA200403328B (en) | 2005-04-13 |
| JP2005509002A (ja) | 2005-04-07 |
| NO20042440L (no) | 2004-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580744A2 (es) | Forma de dosificacion oral de un profarmaco de sulfonamida | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
| AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
| KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
| DK1313467T3 (da) | Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923 | |
| DK0715623T3 (da) | Blodpladeaggregationsinhibitorer | |
| HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| TNSN04137A1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
| ES2150489T3 (es) | 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas. | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
| BR0014902A (pt) | Formulações orais para compostos antitumorais | |
| RU2007131435A (ru) | Противоопухолевое средство | |
| NO20026123D0 (no) | Farmasöytiske sammensetninger | |
| DE69315699D1 (de) | Inhibitoren gegen die aggregation von blutplättchen | |
| DK0804418T3 (da) | Platelataggregationshæmmere | |
| CO5700738A2 (es) | Profarmaco de celecoxib | |
| GT199800039A (es) | Atropisomeros de 3-heteroaril-4(3h)-quinazolinonas. | |
| ECSP066274A (es) | Saquinavir mesilato, forma de dosificacion oral | |
| ES2179526T3 (es) | Analogos y profarmacos del paclitaxel solubles en agua. | |
| ES2197781B1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |